On September 15, 2009
Winners and Losers in the New Elan-J&J Deal
Johnson & Johnson and Elan have altered their deal to exclude the Biogen drug Tysabri from their pact. J&J will now pay $885 million and for 18.4 percent of Elan, plus $500 million for its Alzheimer’s drugs, including bapineuzumab. That acquisition will be the basis of a new J&J unit, Janssen Alzheimer Immunotherapy. The move was predicted by BNET yesterday. Here are the winners and losers in the deal: Winner: Elan. It started with a deal worth $1.5 billion to include MS drug Tysabri and ended with a deal worth $1.4 billion, minus Tysabri — just 7.7 percent less. Loser: J&J. The company just paid $1.4 billion so Elan and Biogen can keep Tysabri, when previously it was willing to…
0 Comments